Yechiel Goldman

Yechiel holds a Ph.D. in Cancer research from the Weizmann Institute of Science. Over the past 20 years he has gained wide-ranging experience as a regulatory affairs professional in the biotechnology-pharmaceutical sector in both biotech start-up companies and Teva. During this period, Yechiel has written, reviewed, edited and assembled a wide variety of CMC, nonclinical, clinical, regulatory, patent and business documentation. He has extensive hands-on experience supporting product development in oncology (small-molecule drugs, cell therapy), nephrology (cell and cell-derived therapies), neurology (small-molecule drugs, mAb, cell therapy), ophthalmology (small-molecule drug), endocrinology (peptide-based drugs) and spinal-cord injury (cell therapy). Yechiel has also participated in due diligence evaluations of oncology candidate projects.